local_hospital

Azienda Ospedaliera Santobono Pausilipon

Address
lock Available on a paid plan

Hematologic Malignancies and Leukemia Research

At Azienda Ospedaliera Santobono Pausilipon in Naples, a major focus is hemic and lymphatic diseases, especially pediatric acute lymphoblastic leukemia, acute myeloid leukemia, and relapsed or high-risk blood cancers. The trials are designed to improve survival, refine treatment strategies, and test newer immunotherapy and targeted approaches for children and adolescents.

  • Studies in acute lymphoblastic leukemia, including relapsed, refractory, and Philadelphia chromosome-positive disease
  • Research in acute myeloid leukemia, including genetic subtypes and treatment-resistant cases
  • Evaluation of immunotherapy, targeted therapy, and treatment intensification to improve outcomes
  • Work on hematopoietic stem cell transplantation and post-transplant relapse prevention

This program reflects a strong commitment to better disease control, safer treatment, and more personalized care for young patients with complex blood cancers.

Pediatric Solid Tumors and Neuro-oncology

Clinical research here also covers neoplasms of the brain and soft tissues, with studies in neuroblastoma, glioma, medulloblastoma, ependymoma, diffuse intrinsic pontine glioma, osteosarcoma, and Ewing sarcoma. These trials aim to improve tumor control, survival, and quality of life through better systemic therapy and radiation-based strategies.

  • Trials in high-risk neuroblastoma to strengthen treatment response and reduce relapse
  • Studies in brain tumors such as glioma, medulloblastoma, ependymoma, and DIPG
  • Research in Ewing sarcoma and osteosarcoma to compare treatment approaches and improve outcomes
  • Testing of targeted and immunotherapy options for difficult-to-treat pediatric tumors

The site’s oncology team is involved in studies that seek more effective treatment combinations while limiting long-term toxicity in children and young adults.

Skin Injury, Burns, and Reconstructive Care

A notable area of research at Azienda Ospedaliera Santobono Pausilipon involves skin and connective tissue diseases, especially severe burns and large skin defects in children and adults. These trials focus on improving wound closure, scar quality, and recovery after major skin injury.

  • Studies in deep partial and full-thickness burns
  • Research for large full-thickness skin defects in children and adults
  • Evaluation of new skin graft and wound repair approaches
  • Assessment of healing outcomes and reduction of scarring

This work aims to support better reconstructive care and faster recovery after severe tissue damage.

Rare Blood Disorders and Bleeding Conditions

The site also conducts trials in hemophilia and inherited bleeding disorders, within the broader field of hemic diseases. These studies are intended to improve bleeding control, safety, and day-to-day management for children with rare coagulation disorders.

  • Research in hemophilia A and severe inherited von Willebrand disease
  • Evaluation of treatments for non-surgical bleeding episodes
  • Studies of hemostatic efficacy and treatment tolerability in pediatric patients
  • Support for safer care in children with chronic bleeding risk

These trials contribute to more reliable bleeding prevention and improved quality of life for affected families.

Neuromuscular and Digestive System Research

Additional studies at the site address nervous system diseases and digestive system diseases, including generalized myasthenia gravis, gastrointestinal graft-versus-host disease, and bowel preparation in children. The purpose is to improve symptom control, treatment safety, and supportive care in complex pediatric conditions.

  • Trials in generalized myasthenia gravis to assess safety and long-term tolerability of newer treatments
  • Research in gastrointestinal aGvHD to help children after prior treatment failure
  • Studies on bowel cleansing for pediatric colonoscopy preparation
  • Supportive-care research aimed at improving comfort and treatment success

Together, these studies show a broad clinical research portfolio that extends beyond oncology into rare neurological and gastrointestinal care.

Site Overview

assignment
39
connected trials
corporate_fare
29
sponsors
science
99
IMPs

Activity Indicator

Last 6 months

1
Trials started
-86% vs previous period.
7
Trials started 6–12 months ago
39
Total trials linked
Highly Active
trending_downDeclining-86%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 2 of 7 therapeutic areas and 15 of 99 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 94 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
25
Sponsors (total)
29
Active sponsors
19

Sponsor Network

Top 19 by active trials.

lock +18 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +7 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 566 other sites in Italy

description
Trial volume
39
Outperforms 81% of sites
public
Therapeutic diversity
7areas
Outperforms 78% of sites
groups
Sponsor diversity
29sponsors
Outperforms 82% of sites

Therapeutic Area Benchmark — Italy

Select a therapeutic area to compare against other sites in Italy.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Italy

Market Share

Country: Italy

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Azienda Ospedaliera Santobono Pausilipon

lock Showing 1 of 39 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants with Congenital Adrenal Hyperplasia Including a Long-Term ExtensionCrinetics Pharmaceuticals Inc.Phase IVRecruitingMar 2026

IMP list

lock Showing 1 of 99 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Cyclophosphamide13Unknown2015-05-052025-12-24

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.